HOOKIPA Pharma Reports Second Quarter 2020 Financial Results and Provides a Corporate Update
(WorldNews Health)

PDF Version NEW YORK and VIENNA, Austria, Aug. 13, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, `HOOKIPA`), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today reports its financial results for the second quarter ended June 30, 2020 and provides a corporate update. `In the second quarter, we released positive interim safety and immunogenicity results from our Phase 2 trial of HB-101 to prevent Cytomegalovirus (CMV) infections. HB-101 was observed to be well tolerated and immunogenic in patients with end-stage kidney disease. Antibody and T cell immunogenicity data confirm our Phase...